UCB announced a definitive agreement to acquire Candid Therapeutics, a clinical-stage biotechnology company focused on T-cell engager therapies for autoimmune ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Mergers and Acquisitions